| A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor | A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor | ChiCTR2000032915 |
| A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients | A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients | ChiCTR2000033049 |
| Adherence to malaria treatment policy and prevalence of Pfkelch13 and background mutations associated with artemisinin resistance emergence in Plasmodium falciparum parasites in Uganda | Predictors of local emergence and spread of artemisinin resistance among Ugandan plasmodium falciparum parasites | ISRCTN12267960 |
| Investigation of the effect of artemisinin and Dermaneh and Afsantinin the treatment of coronavirus COVID-19 virus | Investigation of the effect of artemisinin Capsules and Dermaneh (Artemisia persica)and Afsantin)Artemisia absinthium( Capsules in the treatment of coronavirus COVID-19 virus in Afzalipour hospital,kerman, 2020 | IRCT20201027049164N6 |
| A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects | A Prospective, Randomized, Multi-center, Open Label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg Capsule in Treatment of Adult Subjects With COVID-19 | NCT05004753 |
| A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects | A Double Blind, Randomized, Placebo Controlled, Multi Center Study of OT-101 in Hospitalized COVID-19 Subjects | NCT04801017 |
| Efficacy and safety of artemisinin-based combinations: artesunate+amodiaquine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum in the sites of BUHIGA, KAZIRABAGENI and KIGOBE MUTOYI in KARUZI , MAKAMBA, BUJUMBURA MAIRIE et GITEGA provinces, respectively, BURUNDI | Efficacy and safety of artemisinin-based combinations: artesunate+amodiaquine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum in the sites of BUHIGA, KAZIRABAGENI and KIGOBE MUTOYI in KARUZI , MAKAMBA, BUJUMBURA MAIRIE et GITEGA provinces, respectively, BURUNDI | ACTRN12616001006437 |
| Severe Malaria in Remote Areas- Closing the Evidence Gap | Severe Malaria Treatment with Rectal Artesunate and Artemisinin-based Combination Therapy in Remote Settings | NCT06806956 |
| Project on Fast Control and Elimination of Malaria by Source Eradication Pilot Study on Mass Drug Administration by using Artemisinin-based Combination Therapy in Anjouna, Comoros | Project on Fast Control and Elimination of Malaria by Source Eradication Pilot Study on Mass Drug Administration by using Artemisinin-based Combination Therapy in Anjouna, Comoros | ChiCTR-EOB-15006625 |
| Effectiveness of mosquito repellent for the prevention of malaria in Myanmar | Effectiveness of mosquito repellent delivered through village health volunteers on malaria incidence in artemisinin resistance containment programs in South-East Myanmar | ACTRN12616001434482 |
| Artesunate-pyronaridine and artemisinin-naphthoquine combination therapies for Papua New Guinean children with uncomplicated malaria infections | Efficacy of artesunate-pyronaridine and artemisinin-naphthoquine combination therapies compared with standard artemether-lumefantrine in children from Papua New Guinea with uncomplicated malaria who are monitored for recurrent malaria over 42 days post-treatment | ACTRN12610000913077 |
| Multiple-dose pharmacokinetics and ex vivo pharmacodynamics of the fixed-dosed artemisinin based combination therapies (ACTs) of the antimalarial drugs Artequick (artemisinin-piperaquine) and Coarsucam (artesunate-amodiaquine) in healthy male Vietnamese volunteers | Multiple-dose pharmacokinetics and ex vivo pharmacodynamics of the fixed-dosed combinations of Artequick (artemisinin-piperaquine) and Coarsucam (artesunate-amodiaquine) in healthy male Vietnamese volunteers | ACTRN12609000846224 |
| Pilot Study: Comparison of the efficacy of artemisinin plus piperaquine (Artequick), artesunate plus amodiaquine (Coarsucam) and artesunate plus azithromycin for the treatment of Plasmodium falciparum malaria in Vietnam | Pilot Study: Comparison of the efficacy of artemisinin plus piperaquine (Artequick), artesunate plus amodiaquine (Coarsucam) and artesunate plus azithromycin for the treatment of Plasmodium falciparum malaria in Vietnam | ACTRN12609000816257 |
| Artemisinin to Reduce The Symptoms of Schizophrenia | Double-Blind Trial of Artemisinin to Reduce The Symptoms of Schizophrenia | NCT00753506 |
| A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria | A Pilot, Double-blind, Randomized, Parallel-group, Placebo-controlled, Exploratory Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria | NCT04020653 |
| Efficacy of dual parenteral artemisinin-based combination therapy for cerebral malaria in a randomized control trial in Nigerian children. | Efficacy of dual parenteral artemisinin-based combination therapy for cerebral malaria in a Tripple blind randomized control trial in Nigerian children. | PACTR202102893629864 |
| Artemisinin Combination Therapies (ACTs) efficacy for uncomplicated falciparum malaria treatment in Burkina Faso | Efficacy and tolerability of artemether lumefantrine and amodiaquine artesunate for the treatment of uncomplicated falciparum malaria in Burkina Faso | ISRCTN90823663 |
| Artemisinin Resistance in Bangladesh | Artemisinin Resistance in Bangladesh | NCT00639873 |
| Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19 | A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19 | PACTR202012892855610 |
| Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria | A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains | NCT01374581 |
| An RCT to measure the impact of retreatment with artemisinin-based combination on malaria incidence and resistant strains selection | A Randomized Clinical Trial to measure the impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains | PACTR201203000351114 |
| Evaluation of the combined effect of Hesperidin,Artemisinin- Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19 | effect of Hesperidin,Artemisinin- Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19 | IRCT20181030041504N1 |
| Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia | A Double-Blind, Randomized, Placebo-Controlled Trial of Artemisinin as an Add-on Therapy to Risperidone in the Treatment of Drug-Naive First-Episode Patients With Schizophrenia | NCT01391403 |
| Phase IV study to evaluate the safety and efficacy of Artemisinin- a herbal supplement on COVID-19 subjects | A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19 | CTRI/2020/09/028044 |
